Physician profile
Mohammad Pervaiz
NPI 1205058690
$11,395.07
in general payments reported to CMS, 2019-2025
18 companies · $2,100 in 2025
The $2,100 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $837 · 2021: $525 · 2022: $572 · 2023: $3,037 · 2024: $2,983 · 2025: $2,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,362 · Food and Beverage: $2,237 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,362.34 |
| Food and Beverage | $2,237.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,520.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,503.36 | 2021-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $1,671.33 | 2019-2025 | Watchman Flx |
| Edwards Lifesciences Corporation | $1,618.55 | 2020-2024 | Pascal, Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $987.74 | 2020-2024 | Impella |
| Abbott Laboratories | $855.95 | 2020-2024 | |
| Medtronic Vascular, INC. | $751.79 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $434.99 | 2021-2024 | Lifevest |
| Heartflow, INC. | $282.96 | 2023-2025 | Ffrct |
| Kiniksa Pharmaceuticals International, Plc | $52.77 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $42.53 | 2022-2023 | Arcalyst |
| Bard Peripheral Vascular, INC. | $42.20 | 2023 | Lutonix Drug Coated Balloon |
| Novo Nordisk INC | $38.98 | 2023-2025 | Ozempic |
| Genzyme Corporation | $25.93 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.82 | 2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $19.61 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.56 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.89 | 2021 | |
| Elutia, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Pervaiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.